Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Unlabelled: Operative options for the younger patient with an arthritic knee remain controversial. We prospectively followed 1047 patients 55 years old or younger who underwent knee arthroplasty in a community joint registry over a 14-year period. Patients were implanted with 1047 joints of three predominant designs by 48 surgeons in four hospitals associated with a community joint registry. The mean age for this cohort was 49.8 years, and 62.8% (657/1047) of the patients were female. There were a total of 73 revisions performed, 5.6% (37/653) in women and 9.2% (36/394) in men. Cemented TKAs performed best, with a cumulative revision rate of 15.5%, compared to 32.3% in unicompartmental knee arthroplasty (UKA) patients and 34.1% in cementless designs. Men had a higher cumulative revision rate than women, 31.9% compared to 20.6%. Adjusting for implant type and gender, there was no difference in cumulative revision rate based on diagnosis (OA versus other) or age group (< or = 40, 41-45, 46-50, 51-55 years) or between cruciate-retaining and -substituting designs. Eighty five percent of cemented TKA implants survived at 14 years in the population under 55 years of age in this community registry. Cementless designs and UKA increased revision risk independently.
Level Of Evidence: Level II, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/BLO.0b013e31812f79a9 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!